PTC Therapeutics, Inc. stock is up 28.46% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 2 PUTs, 2 CALLs. 100% of analysts rate it a buy.
PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.